Background Cisplatin-based adjuvant chemotherapy is the standard of care for patients with
resected stage II–IIIA non-small-cell lung cancer (NSCLC). RADIANT and SELECT trial data …

PURPOSE ADJUVANT-CTONG1104 (ClinicalTrials. gov identifier: NCT01405079), a
randomized phase III trial, showed that adjuvant gefitinib treatment significantly improved …

Background Adjuvant chemotherapy after radical resection of stage IIIA non-small-cell lung
cancer (NSCLC) has quite poor outcomes. We aimed to investigate whether adjuvant …

9005 Background: ADJUVANT-CTONG1104, a randomized phase 3 trial showed adjuvant
gefitinib treatment significantly improved disease-free survival (DFS) vs standard doublet …

Introduction Currently, limited data on tyrosine kinase inhibitors as neoadjuvant therapy
exist. This prospective study aimed to investigate the efficacy and safety of preoperative …

LBA7005 Background: In meta-analyses, platinum-based adjuvant (adj) chemotherapy (CT)
in completely resected NSCLC increased cure rate by∼ 5%. At BR. 19 initiation, adj study …

Background Postoperative adjuvant cisplatin-based chemotherapy had been the standard
care in patients with completely resected high-risk stage IB to IIIA non-small cell lung cancer …

PURPOSE To assess the benefits of epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitors as neoadjuvant/adjuvant therapies in locally advanced EGFR mutation …

PURPOSE To investigate the efficacy of gefitinib as an adjuvant therapy for non–small-cell
lung cancer patients with EGFR mutation. PATIENTS AND METHODS IMPACT …

Purpose Epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitors have proven
efficacy in advanced non–small-cell lung cancer (NSCLC). We hypothesized that erlotinib …